Medicare Part D: Changes Needed to Improve CMS's Recovery Audit Program Operations and Contractor Oversight

Abstract

In 2014, the federal government spent$58 billion on Medicare Part D, the voluntary, outpatient prescription drug coverage program. An estimated$1.9 billion of this total was improper paymentsincluding overpayments or underpayments that may be due to errors, such as the submission of duplicate claims for the same service. In January 2011, CMS began a RAC program in Part D that was intended in part to identify and recoup improper payments, as required under the Patient Protection and Affordable Care Act. The RAC is paid a contingency fee from amounts recovered. GAO was asked to review CMSs Part D RAC program implementation, oversight, and results. GAO examined(1) how CMS has implemented the Part D RAC program and any challenges it faced during implementation; (2) the extent to which CMS has overseen the RACs audit activities; and (3) the results of the RACs work to date and any challenges CMS and the RAC faced in identifying and collecting improper payments. To do this, GAO analyzed the RAC contract and audit documents, and federal statutes and regulations on Part D and federal contracting. GAO also interviewed CMS and RAC officials

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Aug 01, 2015
Accession Number
AD1170192

Entities

People

  • Kathleen M. King

Organizations

  • United States Government Accountability Office

Tags

Communities of Interest

  • Biomedical
  • Cyber
  • Weapons Technologies

DTIC Thesaurus Topics

  • Accountability
  • Acquisition
  • Congress
  • Contractors
  • Contracts
  • Controlled Substances
  • Data Analysis
  • Electronic Mail
  • Governments
  • Health
  • Health Care
  • House Of Representatives
  • Information Security
  • Information Systems
  • Medicare
  • Military Acquisition
  • National Governments
  • Pilot Studies
  • Prescription Drugs
  • Public Health
  • Standards
  • Test And Evaluation
  • United States Government

Readers

  • Breast cancer cell signaling and growth regulation.
  • Clinical Trial Research.
  • Government Contracting/Procurement.